These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8958959)

  • 41. Antitumor activity of type I and type III interferons in BNL hepatoma model.
    Abushahba W; Balan M; Castaneda I; Yuan Y; Reuhl K; Raveche E; de la Torre A; Lasfar A; Kotenko SV
    Cancer Immunol Immunother; 2010 Jul; 59(7):1059-71. PubMed ID: 20217081
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interleukin-12: a cytokine with therapeutic potential in oncology and infectious diseases.
    Gately MK; Gubler U; Brunda MJ; Nadeau RR; Anderson TD; Lipman JM; Sarmiento U
    Ther Immunol; 1994 Jun; 1(3):187-96. PubMed ID: 7584494
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Killing effect of IL-12-activated A-NK cells on human hepatocellular carcinoma HepG-2 cells in vitro].
    Wang ZH; Zhao DL; Zhang CY
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):423-4. PubMed ID: 17974274
    [No Abstract]   [Full Text] [Related]  

  • 44. In vivo antitumor activity of anti-CD3-induced activated killer cells.
    Yun YS; Hargrove ME; Ting CC
    Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
    Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
    Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
    Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interleukin-12: murine models of a potent antitumor agent.
    Brunda MJ; Luistro L; Rumennik L; Wright RB; Wigginton JM; Wiltrout RH; Hendrzak JA; Palleroni AV
    Ann N Y Acad Sci; 1996 Oct; 795():266-74. PubMed ID: 8958938
    [No Abstract]   [Full Text] [Related]  

  • 48. Induction of natural killer cell-dependent antitumor immunity by the Autographa californica multiple nuclear polyhedrosis virus.
    Kitajima M; Abe T; Miyano-Kurosaki N; Taniguchi M; Nakayama T; Takaku H
    Mol Ther; 2008 Feb; 16(2):261-8. PubMed ID: 18059370
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2.
    Glick RP; Lichtor T; de Zoeten E; Deshmukh P; Cohen EP
    Neurosurgery; 1999 Oct; 45(4):867-74. PubMed ID: 10515482
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
    Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
    J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Adenovirus-mediated combined gene therapy of interleukin-18 and interleukin-12 for prostate cancer: an experimental study].
    Cheng B; Nong SJ; Zhang YP
    Zhonghua Yi Xue Za Zhi; 2013 May; 93(20):1590-3. PubMed ID: 24028732
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antitumor effect of alpha-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver.
    Fuji N; Ueda Y; Fujiwara H; Toh T; Yoshimura T; Yamagishi H
    Clin Cancer Res; 2000 Aug; 6(8):3380-7. PubMed ID: 10955826
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Treatment of spontaneous metastatic lung cancer with interleukin-12 gene-modified dendritic cells vaccine].
    Chen JQ; Xiu QY; Shen C; Yan ZM
    Ai Zheng; 2002 Dec; 21(12):1328-31. PubMed ID: 12520741
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interleukin-12 activates NK cells for IFN-gamma-dependent and NKT cells for IFN-gamma-independent antimetastatic activity.
    Hafner M; Falk W; Echtenacher B; Männel DN
    Eur Cytokine Netw; 1999 Dec; 10(4):541-8. PubMed ID: 10586121
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
    Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
    J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Contrasting effects of myeloid dendritic cells transduced with an adenoviral vector encoding interleukin-10 on organ allograft and tumour rejection.
    Lee WC; Qiani S; Wan Y; Li W; Xing Z; Gauldie J; Fung JJ; Thomson AW; Lu L
    Immunology; 2000 Oct; 101(2):233-41. PubMed ID: 11012777
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interleukin-12 induces cytotoxic NK1+ alpha beta T cells in the lungs of euthymic and athymic mice.
    Anzai R; Seki S; Ogasawara K; Hashimoto W; Sugiura K; Sato M; Kumagai K; Takeda K
    Immunology; 1996 May; 88(1):82-9. PubMed ID: 8707355
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radio frequency ablation combined with interleukin-2 induces an antitumor immune response to renal cell carcinoma in a murine model.
    Kroeze SG; Daenen LG; Nijkamp MW; Roodhart JM; de Gast GC; Bosch JL; Jans JJ
    J Urol; 2012 Aug; 188(2):607-14. PubMed ID: 22704448
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.
    Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT
    J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.